Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Public ClinicalTrials.gov record NCT03663712. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Study identification
- NCT ID
- NCT03663712
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Dan Blazer III, M.D.
- Other
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- Talimogene Laherparepvec Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 22, 2019
- Primary completion
- Oct 12, 2022
- Completion
- Oct 12, 2022
- Last update posted
- Nov 19, 2024
2019 – 2022
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Illinois College of Medicine at Chicago | Chicago | Illinois | 60612 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27013 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03663712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03663712 live on ClinicalTrials.gov.